Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

• Status: Active, not recruiting
• Trial end date: 2024-12-01

Summary

Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its complications. Multiple defects, e.g. impaired insulin secretion and impaired insulin action, contribute to the development of the disease. The aim of this study is to test the efficacy and durability of combination of drugs which correct the defects that lead to the development of diabetes on achieving adequate and durable control of blood sugar levels. Achieving adequate and durable control of blood sugar will prevent many of diabetes complications.

• Phase: Phase 4

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio
• Collaborators: American Diabetes Association; Amylin Pharmaceuticals, LLC.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Exenatide; Glyburide; Insulin Glargine; Metformin; Pioglitazone